ClinicalTrials.gg
CompletedNCT02346084Updated Sep 8, 2017

Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults

A Phase 1 interventional study of Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV) in HIV/AIDS, sponsored by International Partnership for Microbicides, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-08.

Sponsored by International Partnership for Microbicides, Inc. (part of Population Council) · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing maraviroc in Acquired Immunodeficiency Syndrome — 2 open to participants now, 2 under way, none of them phase 3. Maraviroc · Acquired Immunodeficiency Syndrome.

Enrollment
19th of 29
19 · median 31
Started
2015
with 2 others
Phase 1
7 of 29
none open now
Registered
21st of 29
by date

Among the 29 studies testing maraviroc in Acquired Immunodeficiency Syndrome, this one is the 19th largest by enrollment, is one of 3 that started in 2015, is one of 7 in phase 1, and was the 21st registered.

Acquired Immunodeficiency Syndrome

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

2 of the 29 studies testing maraviroc in Acquired Immunodeficiency Syndrome are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About maraviroc

Maraviroc: first FDA approval 2007 (SELZENTRY), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing maraviroc in Acquired Immunodeficiency Syndrome, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety, acceptability, and PK/PD profile of maraviroc gel following rectal and vaginal administration. The study also includes oral exposure to maraviroc.

Read the detailed description

Trail 11991 is a Phase 1 randomized, open label, single-site trial. Approximately 19 participants (9 female, 10 male) will be randomized to the 9 female study arms and 4 male study arms with 1-3 participants per arm. The randomization will be completed for the product sequence and the timing of tissue sample collection.

All participants will receive both study products by multiple routes of administration (i.e., PO, PR, [and PV for female participants]), and they will be randomized to the order of product sequence and specimen sampling schedule. The male participants will receive oral and rectal MVC and the female participants will receive oral, rectal, and vaginal MVC, in randomized sequence.

Participant accrual will take approximately 6 months. Male participants will be on study for approximately 9 to 12 weeks. Female participants will be on study for approximately 12 to 16 weeks. The total duration of the study will be approximately 9 months.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age of 18 through 45 at screening, verified per site SOP
  2. Male participants, born male; female participants, born female.
  3. Willing and able to communicate in English
  4. Willing and able to provide written to take part in the study
  5. Willing and able to provide adequate locator information, as defined in site SOP
  6. Availability to return for all study visits, barring unforeseen circumstances
  7. Understands and agrees to local sexually transmitted infection (STI) reporting requirements
  8. -1 seronegative at screening and enrollment
  9. Must be in general good health in the opinion of the investigator
  10. Willing to abstain from insertion of anything in the rectum (e.g., penis, sex toy, medication, enemas) 72 hours before all rectal sampling visits and 72 after rectal visits
  11. Must agree to use study-provided condoms for insertive and receptive intercourse, whether vaginal or anal, for the duration of the study
  12. Must agree not to participate in other concurrent interventional and/or drug trials

    Female participants must meet the following criteria:

  13. Per participant report at Screening:

    1. Not pregnant or breastfeeding
    2. Regular menstrual cycles with at least 21 days between menses
    3. Satisfactory cervical Pap result in the 24 calendar months prior to Enrollment consistent with Grade 0 according to the Female Genital Grading Table for Use in Microbicide Studies Addendum 1 to the DAIDS Table for Grading Adult and Pediatric Adverse Events, Version 1.0, December 2004 (Clarification dated August 2009), or satisfactory evaluation with no treatment required of Grade 1 or higher Pap result per American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines in the 12 calendar months prior to Enrollment.
    4. Willing to abstain from vaginal insertion of anything (e.g., penis, sex toy, tampon, medication, douche) for 72 hours before all cervicovaginal sampling visits and 1 week after cervical biopsy visits
  14. Per participant report at Enrollment:

    e) Using an effective method of and intending to continue use of an effective method for the duration of study participation. Effective methods include hormonal methods (except contraceptive vaginal rings), intrauterine device (IUD) inserted at least 28 days prior

    Male participants must meet the following criteria:

  15. Per participant report at Enrollment:

    1. Using an effective method of contraception and intending to continue use of an effective method for the duration of study participation. Effective methods include male condoms, surgical sterilization, being a man who identifies as a man who has sex with men exclusively, sexually abstinent for the past 90 days, and/or female partner use of hormonal contraception, intrauterine device [IUD], or surgical sterilization

Exclusion criteria

Exclusion Criteria:

  1. Undergoing or completed gender reassignment
  2. Participant reports any of the following at Screening:

    1. Post-exposure prophylaxis for exposure within 4 weeks prior to screening
    2. Reports history of unprotected insertive or receptive anal intercourse within 3 months prior to screening
    3. History of sexually transmitted disease in the last 3 months
    4. Known HIV-infected partners
    5. Non-therapeutic injection drug use in the 12 months prior to screening
    6. History of recurrent urticaria
    7. Allergy to soy, soybeans, peanuts, methylparaben, propylparaben, or sorbic acid
    8. Use of antiretroviral medications with activity against HIV within the 4 weeks prior to the Enrollment
    9. Use of systemic immunomodulatory medications within the 4 weeks prior to the Enrollment
    10. Use of vaginally or rectally administered medications or products (including condoms) containing Nonoxynol-9 (N-9) within the 4 weeks prior to the Enrollment
    11. Participating in another research study involving drugs or medical devices within the 4 weeks prior to the Enrollment
    12. Has plans to relocate away from the study site area during the period of study participation
  3. Per participant report at screening, anticipated use and/or unwillingness to abstain from the following medications during the period of study participation:

    1. Heparin, including Lovenox® (enoxaparin sodium)
    2. Warfarin
    3. Plavix® (clopidogrel bisulfate)
    4. Any other drugs that are associated with increased likelihood of bleeding following mucosal (e.g., daily high dose aspirin (> than 81 mg), NSAIDs, or Pradaxa®)
    5. Rectally or vaginally administered medications (including over-the-counter products)
    6. Use of potent inhibitors (e.g., ketoconazole and clarithromycin), and CYP3A inducers (e.g., anti-convulsants and St.John's wort)
    7. Multiple dose dexamethasone
    8. Antiretroviral medications with activity against HIV
  4. History of significant gastrointestinal bleeding in the opinion of the investigator
  5. Abnormalities of the cervical, vaginal, or colorectal mucosa, or significant symptom(s), which in the opinion of the clinician represents a to protocol-required biopsies (including but not limited to presence of any unresolved injury, infectious or inflammatory condition of the local mucosa, and presence of symptomatic external hemorrhoids).
  6. (BMI) \< 18 or > 35 kg/m2
  7. At screening: participant-reported symptoms, and/or clinical or laboratory diagnosis of active rectal or reproductive tract infection requiring treatment per current CDC guidelines or symptomatic urinary tract infection (UTI). Infections requiring treatment include symptomatic bacterial vaginosis, symptomatic vaginal candidiasis, other vaginitis, trichomoniasis, Chlamydia (CT), gonorrhea (GC), syphilis, active HSV lesions, chancroid, pelvic inflammatory disease, genital sores or ulcers, cervicitis, or symptomatic genital warts requiring treatment. Note that an HSV-1 or HSV-2 seropositive diagnosis with no active lesions is allowed, since treatment is not required. Note: In cases of genital GC/CT identified at screening, one re-screening 2 months after screening visit will be allowed
  8. Has any of the following laboratory abnormalities at Screening:

    CHARM-03, Version 1.0 28 31st July 2014

    1. \< 10.0 g/dL
    2. count less than 100,000/mm3
    3. White blood cell count \< 2,000 cells/mm3 or > 15,000 cells/mm3
    4. Calculated ≤ 70 mL/minute using the Cockcroft-Gault equation
    5. (ALT) and/or aspartate aminotransferase (AST) > 2.5× the site laboratory
    6. Total > 2.5 ULN
    7. ≥ +1 glucose or +2 protein on urinalysis (UA)
    8. (INR) test > 1.5× the site laboratory upper limit of normal (ULN)
    9. Positive for surface antigen (HBsAg)
    10. Positive for antibody (HCV Ab)
    11. CCR5 Δ 32 homozygous or heterozygous
  9. Any other condition or prior therapy that, in the opinion of the investigator, would preclude , make study participation unsafe, make the individual unsuitable for the study or unable to comply with the study requirements. Such conditions may include, but are not limited to, current or recent history of severe, progressive, or uncontrolled substance abuse, or renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, or cerebral disease In addition to the criteria listed above, female participants will be excluded if they meet any of the following criteria:
  10. Participant reports any of the following at Screening:

    1. Last pregnancy outcome or gynecological surgery 90 days or less prior to screening
    2. Intends to become pregnant during the period of study participation
    3. Chronic and/or recurrent symptomatic vaginal candidiasis
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Female Participants - Arms 1A through 9A

    Female Participants 9 Arms (1A through 9A) 3 Product Sequences Product Sequence 1 Rx1- MVC tablet PO Rx2- MVC 1% gel PR Rx3- MVC 1% gel PV Product Sequence 2 Rx1- MVC 1% gel PR Rx2- MVC 1% gel PV Rx3- MVC tablet PO Product Sequence 3 Rx1- MVC 1% gel PV Rx2- MVC tablet PO Rx3- MVC 1% gel PR 3 Biopsy Schedules D8- (\~2-hr after the 8th dose) D9- (\~24-hr after the 8th dose) D10- (\~48-hr after the 8th dose)

    Drug: Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)

  • Experimental
    Male Participants - Arms 1B through 4B

    Male Participants 4 Arms (1B through 4B) 2 Product Sequences 2 biopsy schedules Product Sequence 1 Rx1- MVC tablet PO Rx2- MVC 1% gel PR Product Sequence 2 Rx1- MVC 1% gel PR Rx2- MVC tablet PO Biopsy Schedule D8- (\~2-hr after the 8th dose) D10- (\~48-hr after the 8th dose)

    Drug: Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)

Interventions

  • DrugMaraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)

    Drug page: Maraviroc

    Tablets: daily 300 mg oral maraviroc, Selzentry®,(MVC) for 8 consecutive days Gel: daily rectally administered 1% MVC gel for 8 daily consecutive days Female Participants - will receive an additional third regimen of daily vaginally administered MVC 1% gel for 8 consecutive days. Each treatment regimen will be followed by a washout period of 14 to 21 days. Participants will also be randomized to a biopsy sampling schedule (i.e., D8, D9, or D10 sampling).

    Also known as: Tablet - Selzentry®, (MVC)

06

What researchers measure

Primary outcomes

  1. AEs Grade 2 or higher as defined by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events

    Time frame: Female participants will be on study for approximately 12 to 16 weeks. Male participants will be on study for approximately 9 to 12 weeks. The total duration of the study will be approximately 9 months.

07

Study locations

1 site
  • Magee Women's Hospital of UPMC
    Pittsburgh, Pennsylvania 15213, United States
08

References and documents

Publications

  • McGowan IM, Chawki S, Hendrix CW, Anton PA, Marzinke MA, Brand RM, Engstrom JC, Rohan LC, Abebe KZ, Richardson-Harman N, Siegel A, Reinhart A, Steytler J, Stall R, Spiegel H, Chen B, Achilles SL, Jacobson CE, Khanukova E, Cranston RD. A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study). AIDS Res Hum Retroviruses. 2022 Apr;38(4):269-278. doi: 10.1089/AID.2021.0096. Epub 2021 Sep 14. PubMed 34384282 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Dec 2015 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2015
First posted
Jan 26, 2015
Start
Jan 2015
Primary completionActual
Dec 2015
CompletionActual
Mar 2016
Last update
Sep 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02346084
Responsible party
Sponsor
First posted
Jan 26, 2015
Start date
Jan 2015
Primary completion
Dec 2015
Completion
Mar 2016
Last update
Sep 8, 2017

Study contacts

Ian McGowan, MD, PhD, FRCP
study chair · Magee-Women's Research Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maraviroc

Start the discussion